AllianceBernstein
ORMP icon

AllianceBernstein’s Oramed Pharmaceuticals ORMP Stock Holding History

AllianceBernstein’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-16,700
Closed -$144K – 3343
2022
Q1 		$144K Hold
16,700
– – ﹤0.01% 3062
2021
Q4 		$238K Buy
16,700
+6,700
+67% +$140K ﹤0.01% 3014
2021
Q3 		$220K Hold
10,000
– – ﹤0.01% 3061
2021
Q2 		$134K Buy
+10,000
New +$114K ﹤0.01% 3212
2014
Q2 		– Sell
-55
Closed -$1K – 3578
2014
Q1 		$1K Buy
+55
New +$928 ﹤0.01% 3548

Other funds holding ORMP

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AllianceBernstein's ORMP Position: Q2 2022 in Review

AllianceBernstein sold out of Oramed Pharmaceuticals (ORMP) in Q2 2022, closing a stake of 16,700 shares — an estimated $144K sold.

AllianceBernstein first reported a position in ORMP in Q1 2014 and held it in 5 quarters. The position peaked at $238K in Q4 2021. 88 funds tracked by Wall St. Rank hold ORMP as of Q2 2022.

  • AllianceBernstein reported no remaining Oramed Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • AllianceBernstein sold 16,700 Oramed Pharmaceuticals shares in Q2 2022, an estimated $144K.
  • AllianceBernstein first reported a position in Oramed Pharmaceuticals in Q1 2014 and held it in 5 quarters.
  • AllianceBernstein's Oramed Pharmaceuticals position peaked at $238K in Q4 2021.
  • 88 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2022.

Based on AllianceBernstein's 13F filing for Q2 2022, filed 15 Aug 2022.